Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Proceedings of the American Thoracic Society 4:289-294 (2007)
© 2007 The American Thoracic Society
doi: 10.1513/pats.200701-021AW

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krieg, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krieg, A. M.

Antiinfective Applications of Toll-like Receptor 9 Agonists

Arthur M. Krieg1

1 Coley Pharmaceutical Group, Inc., Wellesley, Massachusetts

Correspondence and requests for reprints should be addressed to Arthur M. Krieg, M.D., Coley Pharmaceutical Group, Inc., 93 Worcester Street, Suite 101, Wellesley, MA 02481. E-mail: akrieg{at}coleypharma.com

ABSTRACT

The innate immune system detects pathogens by the presence of highly conserved pathogen-expressed molecules, which trigger host immune defenses. Toll-like receptor (TLR) 9 detects unmethylated CpG dinucleotides in bacterial or viral DNA, and can be stimulated for therapeutic applications with synthetic oligodeoxynucleotides containing immune stimulatory "CpG motifs." TLR9 activation induces both innate and adaptive immunity. The TLR9-induced innate immune activation can be applied in the prevention or treatment of infectious diseases, and the adaptive immune–enhancing effects can be harnessed for improving vaccines. This article highlights the current understanding of the mechanism of action of CpG oligodeoxynucleotides, and provides an overview of the preclinical data and early human clinical trial results, applying these TLR9 agonists in the field of infectious diseases.

Key Words: innate immunity • dendritic cell • infection • cytokine




This article has been cited by other articles:


Home page
Infect. Immun.Home page
Z. G. Ramirez-Ortiz, C. A. Specht, J. P. Wang, C. K. Lee, D. C. Bartholomeu, R. T. Gazzinelli, and S. M. Levitz
Toll-Like Receptor 9-Dependent Immune Activation by Unmethylated CpG Motifs in Aspergillus fumigatus DNA
Infect. Immun., May 1, 2008; 76(5): 2123 - 2129.
[Abstract] [Full Text] [PDF]


Home page
CVIHome page
V. A. Stewart, S. McGrath, A. M. Krieg, N. S. Larson, E. Angov, C. L. Smith, T. G. Brewer, and D. G. Heppner Jr.
Activation of Innate Immunity in Healthy Macaca mulatta Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques
Clin. Vaccine Immunol., February 1, 2008; 15(2): 221 - 226.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Thoracic Society.